Vator Securities advises Xbrane Biopharma on 238 MSEK Directed and Rights Issue
The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.
Read More
Xlucane Product Launch Insight with STADA and Xbrane Biopharma
Vator Securities hosted a Product Launch Insight event for Xlucane together with German STADA Arzneimittel and Xbrane Biopharma yesterday, 11 April 2019.
Read More
Vator Securities advises Xbrane Biopharma on SEK 59 million Rights Issue
Vator Securities acted Financial Adviser in connection with the transaction raising SEK 59 million.
Read More
Schibsted, Resurs Bank och Moore Strategic Ventures invest in Dicopay
Dicopay, the leading supplier of digital and mobile services for invoicing and direct payments, announced today that it has raised SEK 42 million to help accelerate the roll out of its services and expand its offering.The investment round was led by Schibsted Growth, and also includes Resurs Bank as an investor and commercial partner, and Moore Strategic Ventures as an investor and financial partner.
Read More
Vator Securities advises Ascelia Pharma on SEK 200 million IPO
Vator Securities acted as Sole Global Coordinator and Bookrunner in the oversubscribed Ascelia Pharma IPO offer. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the Offering.
Read More
Vator Securities advises Visiopharm on a DKK100 million private placement
ATP, the Danish Growth Fund and the C. L. David Foundation and Collection are among the new investors. The increased capital commitment is an essential part of the company’s growth strategy within the field of tissue diagnostics- and research software for cancer.
Read More
Vator Securities Sole Bookrunner in Nanoform SEK 71 million private placement
The private placement was directed to Swedish and Finnish, HNWI, family offices and institutional investors where Mandatum Life Insurance Company (Sampo Group) acted as anchor investor.
Read More
Vator Securities advises AlzeCure Pharma on SEK 40 million directed share issue
Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 40 million.
Read More